Delving into the Latest Updates on Voglibose/Metformin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Metformin/voglibose, Voglibose/metformin, Vogmet

+ [5]

Target

MGAM x PRKAB1

Mechanism

MGAM inhibitors(Maltase-glucoamylase inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Athena Pharmaceutiques SAS

Active Organization

Athena Pharmaceutiques SAS

Inactive Organization

HK inno.N Corp.

Drug Highest PhaseApproved

First Approval Date

IN (01 Jan 2011),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure

Molecular FormulaC4H12ClN5

InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N

CAS Registry1115-70-4

View All Structures (2)

This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma.

Start Date01 Jan 2016

Sponsor / Collaborator

University of Iowa

[+1]

NCT01370707 / CompletedPhase 3

A Randomized, Double-blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Patients With Type 2 Diabetes and Inadequate Glycemic Control ; Phase III Study

The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.

Start Date01 Apr 2011

Sponsor / Collaborator

HK inno.N Corp.

100 Clinical Results associated with Voglibose/Metformin Hydrochloride

Login to view more data

100 Translational Medicine associated with Voglibose/Metformin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Voglibose/Metformin Hydrochloride

Login to view more data

1

Literatures (Medical) associated with Voglibose/Metformin Hydrochloride

01 Jan 2019·Diabetes & Metabolism JournalQ3 · MEDICINE

Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Q3 · MEDICINE

ArticleOA

Author: Park, Sung Woo ; Park, Joong Yeol ; Kim, Sung Rae ; Son, Hyun Shik ; Choi, Sung Hee ; Song, Young Duk ; Park, Tae Sun ; Cha, Bong Soo ; Lee, Kwan Woo ; Min, Kyung Wan ; Yoon, Kun Ho ; Lee, Moon Kyu ; Kim, Yong Seong ; Kim, In Joo ; Baik, Sei Hyun ; Kim, Doo Man ; Yu, Jae Myung ; Jeong, In Kyung ; Lee, In Kyu ; Oh, Tae Jung ; Park, Jeong Hyung

BACKGROUNDCombination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus.METHODSA total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24.RESULTSThe reduction in the levels of HbA1c was -1.62%±0.07% in the vogmet group and -1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (-1.63 kg vs. -0.86 kg, P=0.039).CONCLUSIONVogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.

100 Deals associated with Voglibose/Metformin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10BD	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	IN	Athena Pharmaceutiques SAS	01 Jan 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	KR	HK inno.N Corp.	01 Apr 2011
Diabetes Mellitus	Phase 3	-	HK inno.N Corp.	01 Oct 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01370707 (Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	187	Voglibose Plus Metformin	(qzpgirrjdw) = mdmozviaku gmwbknnxls (pjfmcqfopg, 0.07) View more	Superior	01 Jun 2019
				metformin	(qzpgirrjdw) = bfhkpzoyqf gmwbknnxls (pjfmcqfopg, 0.07) View more